濮阳东方医院看妇科病价格不贵(濮阳东方男科医院评价好收费低) (今日更新中)

HARBIN, March 2 (Xinhua) -- A therapeutic apparatus to treat Parkinson's disease has been developed in northeast China's Heilongjiang Province, according to the provincial science and technology department. It is a worldwide breakthrough in treating the disease with transcranial magnetic stimulation, concluded an expert panel with the Heilongjiang Provincial Department of Science and Technology.The team said it came to the conclusion after evaluating technical documents and clinical test results Monday.This is the first time that transcranial magnetic stimulation has been adopted to treat Parkinson's disease, said Sun Zuodong, chairman of Aobo Medicine Apparatus Co., Ltd. (AMA), the developer based in the provincial capital Harbin.Transcranial magnetic stimulation is a noninvasive method which causes depolarization in the brains' neurons so as to restore the functions of brain nerves.The apparatus consists of three parts, namely brain wave stimulator, field effect cap and multiplier, said Sun.Clinical tests over more than 100 patients showed that the apparatus had a 70 percent success rate in reducing the disease's symptoms, according to Wang Aili, planning manager of AMA.The new equipment will help generation of dopamine, the reduction of which within the brain caused the disease, said Wang Weixiang, a consulting doctor with the Heilongjiang Provincial Rehabilitation Hospital.Parkinson's disease is a disorder of the neural system, which leads to limb tremors and difficulty in walking and other movements.China has 2 million patients suffering from Parkinson's disease, mostly people over the age of 50, and the number is increasing by 100,000 annually, said Dr. Wang.

LOS ANGELES, April 14 (Xinhua) -- Customer complaints of an "uncharacteristic odor" prompted Johnson & Johnson to recall about 57,000 bottles of the prescription anti-seizure drug, Johnson & Johnson announced on Thursday.The recall affects two lots of the Topamax 100 mg tablets made by the company's Ortho-McNeil Neurologics division, Johnson & Johnson said.The drug was shipped and distributed between Oct. 19, 2010 and Dec. 28, 2010 in the United States and Puerto Rico.There were four consumer complaints about an odor believed to be caused by trace amounts of the chemical TBA (2,4,6 tribromoanisole), which is applied to wooden pallets used to transport and store packaging materials, Johnson & Johnson said.The recall is not expected to lead to a product shortage at the market, Ortho-McNeil Neurologics said.Similar complaints of a moldy, musty odor have led to the recalls of millions of bottles of Tylenol, Motrin and Benadryl products earlier.Last month, the U.S. government said it was taking over three Tylenol plants operated by McNeil, and the Food and Drug Administration launched a criminal investigation into safety issues at the factories, CNN reported.

WASHINGTON, May 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Sutent to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.This is the second new approval by the FDA to treat patients with this disease. On May 5, the agency approved Afinitor."FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss, stomach pain, changes in hair color, inflammation of the mouth, and a decrease in infection-fighting white blood cells.Sutent is marketed by New York City-based Pfizer.

VIENNA, March 28 (Xinhua) -- Stress hormone is helpful in alleviating acrophobia, a morbid fear of great heights, according to a study by Austrian scientists.They published the findings in the recent Proceedings of the National Academy of Sciences of the United States of America.Frank H. Wilhelm, professor from the Department of Clinical Psychology, Psychotherapy and Health Psychology at the University of Salzburg, Austria, carried out the first study demonstrating the clinical effectiveness of hormones released at periods of high stress in anxiety.The study found hormones and other drugs could be a good addition to behavioral treatment of several anxiety disorders.People with acrophobia have formed a so-called fear memory, which could be activated when the fear-causing stimulus occurs. They tend to react with feelings of extreme fear and anxiety to the ride in a glass elevator.Hence, scientists conducted a confrontation therapy, trying to mask this memory.A total of 40 experimental subjects had been put in a safe environment to constantly confront the fear-inducing stimulus, until they had a new reaction to the perceived threat.Observations also suggested hormones released in high stress had impact on learning and memory.Additionally, stress hormones were believed to facilitate the storage of new, anxiety-free competence and experienced confidence in the therapy. Animal studies have shown that this emotional relearning benefits from cortisol, one of the stress hormones.

BEIJING, May 14 (Xinhua) -- The uranium subsidiary of China Guangdong Nuclear Power Group (CGNPG) has said it is developing two large mines in the mainland.The two mines will be located in south China's Guangdong province and northwest China's Xinjiang Uygur Autonomous Region, according to Saturday's China Daily.The move is likely to add as much as 1,000 tonnes to the country's annual production capacity of the nuclear fuel."The two mines are expected to start operation in 2013, each with an annual production capacity of no more than 500 tonnes," the newspaper quoted Zhou Zhenxing, chairman of CGNPG Uranium Resources Co (CGNPG-URC) as saying.

来源：资阳报